Art

J-GLOBAL ID：201802271712010116   Reference number：18A1496200

Effect of Canagliflozin on endothelial function in diabetic patients with suspected coronary artery disease: retrospective preliminary pilot study

冠動脈疾患疑いのある糖尿病患者における内皮機能に与えるカナグリフロジンの効果;後ろ向き予備的パイロット試験

Author (3)： Takase Bonpei (Department of Intensive Care Medicine, National Defense Medical College) ,  Higashimura Yuko (Department of Intensive Care Medicine, National Defense Medical College) ,  Hashimoto Kenichi (Department of Intensive Care Medicine, National Defense Medical College)
Material： Vascular Failure (Web)
Volume： 2  Issue： 1  Page： 32-38(J-STAGE)  Publication year： 2018 
JST Material Number： U1444A  ISSN： 2432-4477  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： pilot test ,...
Semi thesaurus term： 冠動脈疾患疑い ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1496200&from=J-GLOBAL&jstjournalNo=U1444A") }}

Author keywords (5)： SGLT2 ,  Diabetes mellitus ,  Flow-mediated vasodilatation ,  EndoPAT2000 ,  DPP4

JST classification (2)： Clinical application of drugs acting on carbohydrate metabolism  (GW13030B) ,  Treatment for metabolic diseases,nutritional diseases.  (GD05030F)

Substance index (1)： Canagliflozin

Reference (30)：

• 1) Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK, et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. PLoS One 2017; 12: e0177646. doi: 10.1371/journal.pone.0177646. eCollection 2017.
• 2) Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al; EMPA-REG OUTCOME. Investigators empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
• 3) Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin cardiovascular assessment study). Circulation 2017 Nov 13. pii: CIRCULATIONAHA.117.032038. doi: 10.1161/CIRCULATIONAHA.117.032038. [Epub ahead of print].
• 4) Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 2017; 16: 138.
• 5) Michel MC, Mayoux E, Vallon V. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn Schmiedebergs Arch Pharmacol 2015; 388: 801-16.

Terms in the title (5)： 冠動脈疾患 ,  糖尿病患者 ,  内皮 ,  カナグリフロジン ,  パイロット試験